Dr. Danielle S. Wallace, M.D
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 72
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 290482 -
Internal Medicine Physician
NY license 290482
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Strong Memorial Hospital Rochester, NY
Medical groups
- University of Rochester (973 clinicians)
- Hematology Clinical Group (81 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 72
- Services billed
- 357
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 15 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Rochester, NY | 32 |
| Bexarotene | 13 |
| Levothyroxine Sodium Other prescribers in Rochester, NY | 13 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Rochester, NY | 13 |
| Prochlorperazine Maleate Other prescribers in Rochester, NY | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 5 payments worth $3,961 in total to this clinician.
| Acrotech Biopharma Inc. | $3,961 |
|---|
| Consulting Fee | $3,961 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Acrotech Biopharma Inc. Nov 14, 2025 | Consulting Fee BELEODAQ · ONCOLOGY | $3,000 |
| Acrotech Biopharma Inc. Nov 13, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $593 |
| Acrotech Biopharma Inc. Nov 13, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $210 |
| Acrotech Biopharma Inc. Nov 14, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $109 |
| Acrotech Biopharma Inc. Nov 14, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $48.80 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $170,309 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Beone Medicines Ltd. · Recruiting · NCT06634589 - Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len
Genentech, Inc. - Study name not reported
Adaptive Biotechnologies Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.